Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis

B. Bulanova Pekova, V. Sykorova, K. Mastnikova, E. Vaclavikova, J. Moravcova, P. Vlcek, L. Lancova, P. Lastuvka, R. Katra, P. Bavor, D. Kodetova, M. Chovanec, J. Drozenova, R. Matej, J. Astl, J. Hlozek, P. Hrabal, J. Vcelak, B. Bendlova

. 2023 ; 30 (12) : . [pub] 20231026

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000390

Thyroid cancer is associated with a broad range of different mutations, including RET (rearranged during transfection) fusion genes. The importance of characterizing RET fusion-positive tumors has recently increased due to the possibility of targeted treatment. The aim of this study was to identify RET fusion-positive thyroid tumors, correlate them with clinicopathological features, compare them with other mutated carcinomas, and evaluate long-term follow-up of patients. The cohort consisted of 1564 different thyroid tissue samples (including 1164 thyroid carcinoma samples) from pediatric and adult patients. Samples were analyzed for known driver mutations occurring in thyroid cancer. Negative samples were subjected to extensive RET fusion gene analyses using next-generation sequencing and real-time PCR. RET fusion genes were not detected in any low-risk neoplasm or benign thyroid tissue and were detected only in papillary thyroid carcinomas (PTCs), in 113/993 (11.4%) patients, three times more frequently in pediatric and adolescent patients (29.8%) than in adult patients (8.7%). A total of 20 types of RET fusions were identified. RET fusion-positive carcinomas were associated with aggressive tumor behavior, including high rates of lymph node (75.2%) and distant metastases (18.6%), significantly higher than in NTRK fusion, BRAF V600E and RAS-positive carcinomas. Local and distant metastases were also frequently found in patients with microcarcinomas positive for the RET fusions. 'True recurrences' occurred rarely (2.4%) and only in adult patients. The 2-, 5-, 10-year disease-specific survival rates were 99%, 96%, and 95%, respectively. RET fusion-positive carcinomas were associated with high invasiveness and metastatic activity, but probably due to intensive treatment with low patient mortality.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000390
003      
CZ-PrNML
005      
20240213093141.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1530/ERC-23-0117 $2 doi
035    __
$a (PubMed)37882481
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bulanova Pekova, Barbora $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic $1 https://orcid.org/000000028571164X
245    10
$a RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis / $c B. Bulanova Pekova, V. Sykorova, K. Mastnikova, E. Vaclavikova, J. Moravcova, P. Vlcek, L. Lancova, P. Lastuvka, R. Katra, P. Bavor, D. Kodetova, M. Chovanec, J. Drozenova, R. Matej, J. Astl, J. Hlozek, P. Hrabal, J. Vcelak, B. Bendlova
520    9_
$a Thyroid cancer is associated with a broad range of different mutations, including RET (rearranged during transfection) fusion genes. The importance of characterizing RET fusion-positive tumors has recently increased due to the possibility of targeted treatment. The aim of this study was to identify RET fusion-positive thyroid tumors, correlate them with clinicopathological features, compare them with other mutated carcinomas, and evaluate long-term follow-up of patients. The cohort consisted of 1564 different thyroid tissue samples (including 1164 thyroid carcinoma samples) from pediatric and adult patients. Samples were analyzed for known driver mutations occurring in thyroid cancer. Negative samples were subjected to extensive RET fusion gene analyses using next-generation sequencing and real-time PCR. RET fusion genes were not detected in any low-risk neoplasm or benign thyroid tissue and were detected only in papillary thyroid carcinomas (PTCs), in 113/993 (11.4%) patients, three times more frequently in pediatric and adolescent patients (29.8%) than in adult patients (8.7%). A total of 20 types of RET fusions were identified. RET fusion-positive carcinomas were associated with aggressive tumor behavior, including high rates of lymph node (75.2%) and distant metastases (18.6%), significantly higher than in NTRK fusion, BRAF V600E and RAS-positive carcinomas. Local and distant metastases were also frequently found in patients with microcarcinomas positive for the RET fusions. 'True recurrences' occurred rarely (2.4%) and only in adult patients. The 2-, 5-, 10-year disease-specific survival rates were 99%, 96%, and 95%, respectively. RET fusion-positive carcinomas were associated with high invasiveness and metastatic activity, but probably due to intensive treatment with low patient mortality.
650    _2
$a mladiství $7 D000293
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    _2
$a dítě $7 D002648
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    12
$a nádory štítné žlázy $x genetika $x patologie $7 D013964
650    _2
$a papilární karcinom štítné žlázy $7 D000077273
650    _2
$a mutace $7 D009154
650    12
$a karcinom $7 D002277
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny c-ret $x genetika $7 D051096
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sykorova, Vlasta $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic
700    1_
$a Mastnikova, Karolina $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic
700    1_
$a Vaclavikova, Eliska $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic
700    1_
$a Moravcova, Jitka $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic
700    1_
$a Vlcek, Petr $u Department of Nuclear Medicine and Endocrinology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Lancova, Lucie $u Department of Nuclear Medicine and Endocrinology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Lastuvka, Petr $u Departments of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Katra, Rami $u Department of Ear, Nose and Throat, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Bavor, Petr $u Department of Surgery, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Kodetova, Daniela $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Chovanec, Martin $u Department of Otorhinolaryngology, 3rd Faculty of Medicine, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Drozenova, Jana $u Department of Pathology, 3rd Faculty of Medicine, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Matej, Radoslav $u Department of Pathology, 3rd Faculty of Medicine, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Astl, Jaromir $u Department of Otorhinolaryngology and Maxillofacial Surgery, 3rd Faculty of Medicine and Military University Hospital, Prague, Czech Republic
700    1_
$a Hlozek, Jiri $u Department of Otorhinolaryngology and Maxillofacial Surgery, 3rd Faculty of Medicine and Military University Hospital, Prague, Czech Republic
700    1_
$a Hrabal, Petr $u Department of Pathology, Military University Hospital, Prague, Czech Republic
700    1_
$a Vcelak, Josef $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic
700    1_
$a Bendlova, Bela $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic
773    0_
$w MED00001521 $t Endocrine-related cancer $x 1479-6821 $g Roč. 30, č. 12 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37882481 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093138 $b ABA008
999    __
$a ok $b bmc $g 2049198 $s 1210084
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 30 $c 12 $e 20231026 $i 1479-6821 $m Endocrine-related cancer $n Endocr Relat Cancer $x MED00001521
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace